|
Jul 21
|
Why Alkermes Tumbled On Its Positive Narcolepsy Study
|
|
Jul 21
|
Takeda Pharmaceutical Receives FDA 510(k) Clearance for Hyqvia Devices
|
|
Jul 21
|
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
|
|
Jul 17
|
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
|
|
Jul 15
|
Takeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA
|
|
Jul 14
|
The No. 1 Key To Wealth, According To Wahei Takeda, the ‘Warren Buffett of Japan’
|
|
Jul 14
|
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Fresh Tariff Warnings
|
|
Jul 14
|
Takeda’s oral narcolepsy drug shines in two Phase III trials
|
|
Jul 14
|
Takeda to seek approval of new kind of narcolepsy drug after study data
|
|
Jul 14
|
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
|
|
Jul 2
|
What's Fueling Tempus AI's Explosive Sales Growth?
|
|
Jul 1
|
FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
|
|
Jun 30
|
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
|
|
Jun 27
|
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
|
|
Jun 27
|
Will Strong Asceniv Sales Drive ADMA Biologics Further?
|
|
Jun 25
|
Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels
|
|
Jun 25
|
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
|
|
Jun 25
|
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
|
|
Jun 24
|
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
|
|
Jun 4
|
EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
|